BioXcel Therapeutics, Inc. Share Price & Technical Analysis
BTAI · $1.13 (-0.88%)
Healthcare / Drug Manufacturers - Specialty & Generic
$1.13
-0.88%
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It…
Price chart
Seasonality
May has 0 positive and 5 negative years (last 5 years shown)
-8% return in May, -26% avg return in past 3 year May month.
-35% return in 2026, -104% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 0% | 6% | -19% | -14% | -8% | – | – | – | – | – | – | – | -35% |
| 25 | -16% | -55% | -17% | -10% | -37% | 50% | -32% | 141% | -35% | -20% | 10% | -27% | -47% |
| 24 | 11% | -2% | -13% | -11% | -29% | -29% | -13% | -45% | -3% | 9% | -39% | -10% | -175% |
| 23 | 35% | 13% | -42% | 10% | -13% | -63% | 33% | -58% | -33% | 57% | -8% | -22% | -91% |
| 22 | -18% | 5% | 15% | -38% | -11% | 11% | 18% | -11% | -12% | 6% | 30% | 26% | 21% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$31.68M
P/E ratio
—
52W high
$8.08
52W low
$1.01
Volume
3,49,298
Beta
0.31
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BioXcel Therapeutics, Inc. share price today?
- BioXcel Therapeutics, Inc. (BTAI) last traded around $1.13 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BTAI have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BTAI. Download the app for real-time alerts.
- How can I analyze BioXcel Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.